ORBERA™ Post-Approval Study

NCT02828657 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 284

Last updated 2020-07-13

No results posted yet for this study

Summary

A prospective, multicenter, open-label, post-approval study of the safety and effectiveness of ORBERA™ as an adjunct to weight reduction for obese adults (22 years of age and older) with a Body Mass Index (BMI) of ≥ 30 kg/m2 and BMI ≤ 40 kg/m2

Conditions

Sponsors & Collaborators

  • Apollo Endosurgery, Inc.

    lead INDUSTRY

Principal Investigators

  • Jose L. Naveira · Apollo Endosurgery, Inc.

  • James M Buswold · Apollo Endosurgery, Inc.

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02828657 on ClinicalTrials.gov